An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder - Preskorn, S H; Baker, B; Kolluri, S (J Clin Psychopharmacol, 2008)
et al.